Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | ESR1 | P03372 | 4/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.33 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3397431 | 1.00 | CYP3A4 (0.39) | CYP3A4TDP1TP53ESR1ESR2 | |
| SCHEMBL34614 | 0.92 | CYP3A4 (0.45) | CYP3A4TDP1TP53ESR1ESR2 | |
| SCHEMBL28509714 | 0.90 | CYP3A4 (0.39) | CYP3A4TDP1TP53ESR1ESR2 | |
| SCHEMBL5076037 | 0.90 | CYP3A4 (0.39) | CYP3A4TDP1TP53ESR1ESR2 | |
| SCHEMBL27863771 | 0.90 | CYP3A4 (0.39) | CYP3A4TDP1TP53ESR1ESR2 | |
| Chloromethane SCHEMBL7930183 | 0.90 | CYP3A4 (0.39) | CYP3A4TDP1TP53ESR1ESR2 | |
| SCHEMBL28811253 | 0.90 | CYP3A4 (0.39) | CYP3A4TDP1TP53ESR1ESR2 | |
| Hydrogen Sulfide SCHEMBL8154468 | 0.90 | TDP1 (0.43) | CYP3A4TDP1TP53ESR1ESR2 | |
| Hydrochloric Acid SCHEMBL11570696 | 0.90 | CYP3A4 (0.43) | CYP3A4TDP1TP53ESR1ESR2 | |
| SCHEMBL3749691 | 0.90 | CYP3A4 (0.43) | CYP3A4TDP1TP53ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1718629-B1 | Benzopyran compounds useful for the treatment of arrhytmia | NISSAN CHEMICAL IND LTD (JP) | 2012-12-26 | — | — | EP | disclosed |
| EP-2310446-A1 | ACTIVATED HALO-CONTAINING ARALKYLSILANE | Momentive Performance Materials Inc. (US) | 2011-04-20 | — | — | EP | disclosed |
| EP-1544187-B1 | 1,7,8-TRIFLUORONAPHTHALENE-2-NAPHTHOL, AND METHODS FOR PRODUCING LIQUID CRYSTAL COMPOUNDS USING SAME | DAINIPPON INK & CHEMICALS (JP) | 2011-02-16 | — | — | EP | disclosed |
| US-7781483-B2 | Benzopyran compound | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2010-08-24 | — | — | US | disclosed |
| WO-2010017370-A1 | ACTIVATED HALO-CONTAINING ARALKYLSILANE | MOMENTIVE PERFORMANCE MATERIALS INC. (US) | 2010-02-11 | — | — | WO | disclosed |
| US-20070299130-A1 | Benzopyran Compound | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2007-12-27 | — | — | US | disclosed |
| US-7214835-B2 | 1,7,8-Trifluoronaphthalene-2-naphthol, and method for producing liquid crystal compound using same | DAINIPPON INK & CHEMICALS, INC. (JP) | 2007-05-08 | — | — | US | disclosed |
| EP-1718629-A2 | BENZOPYRAN COMPOUNDS USEFUL FOR THE TREATMENT OF ARRHYTMIA | Nissan Chemical Industries, Ltd. (JP) | 2006-11-08 | — | — | EP | disclosed |
| US-20060163537-A1 | 1,7,8-Trifluoronaphthalene-2-naphthol, and method for producing liquid crystal compound using same | DAINIPPON INK AND CHEMICALS, INC. (JP) | 2006-07-27 | — | — | US | disclosed |
| WO-2005080368-A2 | BENZOPYRAN COMPOUND USEFUL FOR THE TREATMENT OF ARRHYTMIA | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2005-09-01 | — | — | WO | disclosed |
| EP-1544187-A1 | 1,7,8-TRIFLUORONAPHTHALENE-2-NAPHTHOL, AND METHOD FOR PRODUCING LIQUID CRYSTAL COMPOUND USING SAME | DAINIPPON INK AND CHEMICALS, INC. (JP) | 2005-06-22 | — | — | EP | disclosed |
| EP-0811629-B1 | OPTICALLY ACTIVE BIDENTATE PHOSPHINE LIGAND/PALLADIUM COMPLEX | NISSAN CHEMICAL IND LTD (JP) | 2003-05-02 | — | — | EP | disclosed |
| US-5880301-A | CATALYSTS FOR PREPARATION OF OPTICALLY ACTIVE BETA-HYDROXYKETONES | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 1999-03-09 | — | — | US | disclosed |
| EP-0811629-A1 | OPTICALLY ACTIVE BIDENTATE PHOSPHINE LIGAND/PALLADIUM COMPLEX | NISSAN CHEMICAL INDUSTRIES, LIMITED (JP) | 1997-12-10 | — | — | EP | disclosed |
| US-4092171-A | CHEMICAL SENSITIZERS FOR SILVER HALIDE EMULSIONS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1978-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299130-A1 | Benzopyran Compound | NR0B1, CYP2B6, RYR2 | CYP3A4 224/4885TDP1 4487/4885TP53 4824/4885 |
| US-20060163537-A1 | 1,7,8-Trifluoronaphthalene-2-naphthol, and method for producing liquid crystal compound using same | NOC2L, SNX2, NEFM | CYP3A4 286/4885TDP1 1093/4885TP53 2047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.